bioRxiv Science⌕ Search

Biology subjects

Ruijgrok, P. V.

Publications and source records attributed to Ruijgrok, P. V..

2 recordsLinked to original sources

Engineering filamentous myosins for optical control of contractility

Understanding the behaviors of contractile actomyosin systems requires precise spatiotemporal control of filamentous myosin activity. Here, we develop a tool for optical control of contractility by extending the MyLOV family of gearshifting motors to create engineered filamentous myosins that change velocity in response to blue light. We characterize these minifilaments using in vitro single-molecule tracking assays, contractility assays in reconstituted actin networks, and imaging of contractile phenotypes in Drosophila S2 cells. The minifilaments change speed and/or direction when illuminated, display speeds that fall within and beyond the relevant physiological range, and display high processivities. Additionally, minifilament-driven contraction rates increase in blue light both in vitro and in S2 cells. Finally, we develop an alternative design for minifilaments that only interact processively with actin in blue light. Engineered minifilaments can be used to dissect behaviors such as self-organization and mechanotransduction in contractile systems both in vitro and in cells and tissues.

biophysics↗

A small-molecule myosin inhibitor as a targeted multi-stage antimalarial

Malaria is a devastating disease that resulted in an estimated 627,000 deaths in 2020. About 80% of those deaths were among children under the age of five. Our approach is to develop small molecule inhibitors against cytoskeletal targets that are vital components of parasite function, essential at multiple stages of parasite infection, can be targeted with high specificity, and are highly druggable. Here we describe KNX-115, which inhibits purified Plasmodium falciparum myosin A (PfMyoA) actin-activated ATPase with a potency in the 10s of nanomolar range and >50-fold selectivity against cardiac, skeletal, and smooth muscle myosins. KNX-115 inhibits the blood and liver stages of Plasmodium with an EC50 of about 100 nanomolar, with negligible liver cell toxicity. In addition, KNX-115 inhibits sporozoite cell traversal and blocks the gametocyte to oocyst conversion in the mosquito. KNX-115 displays a similar killing profile to pyrimethamine and parasites are totally killed after 96 hours of treatment. In line with its novel mechanism of action, KNX-115 is equally effective at inhibiting a panel of Plasmodium strains resistant to experimental and marketed antimalarials. In vitro evolution data likely suggests a refractory potential of KNX-115 in developing parasite resistance.

pharmacology and toxicology↗